1.5138
Beyondspring Inc stock is traded at $1.5138, with a volume of 5,819.
It is up +0.25% in the last 24 hours and down -23.93% over the past month.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.
See More
Previous Close:
$1.51
Open:
$1.54
24h Volume:
5,819
Relative Volume:
0.02
Market Cap:
$61.27M
Revenue:
$1.88M
Net Income/Loss:
$-15.57M
P/E Ratio:
-3.7845
EPS:
-0.4
Net Cash Flow:
$-50.09M
1W Performance:
-11.47%
1M Performance:
-23.93%
6M Performance:
-32.12%
1Y Performance:
-8.81%
Beyondspring Inc Stock (BYSI) Company Profile
Name
Beyondspring Inc
Sector
Industry
Phone
646-528-4184
Address
100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR, FLORHAM PARK, NY
Compare BYSI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
BYSI
Beyondspring Inc
|
1.49 | 62.09M | 1.88M | -15.57M | -50.09M | -0.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.91 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.61 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.65 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.52 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.23 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Beyondspring Inc Stock (BYSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-21 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-02-21 | Downgrade | Jefferies | Buy → Hold |
| Dec-01-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-01-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-09-21 | Initiated | Robert W. Baird | Outperform |
| Aug-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-05-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-11-21 | Initiated | BofA Securities | Buy |
| Dec-29-20 | Initiated | Evercore ISI | Outperform |
| Feb-07-20 | Initiated | Jefferies | Buy |
| Jan-10-20 | Initiated | Nomura | Buy |
| Dec-03-19 | Initiated | William Blair | Outperform |
| Jul-10-19 | Reiterated | H.C. Wainwright | Buy |
| Apr-30-19 | Downgrade | Maxim Group | Buy → Hold |
| Oct-25-18 | Reiterated | Maxim Group | Buy |
View All
Beyondspring Inc Stock (BYSI) Latest News
Breakout Zone: How BeyondSpring Inc stock compares to market leaders2025 EndofYear Setup & Short-Term Trading Alerts - moha.gov.vn
Why BeyondSpring Inc. stock could benefit from AI revolutionVolatility Index Analysis & Free Significant Capital Appreciation - bollywoodhelpline.com
S P Trends: Does BeyondSpring Inc stock trade at a discount to peersMarket Movement Recap & Precise Swing Trade Alerts - moha.gov.vn
BeyondSpring Inc. (NASDAQ:BYSI) Sees Large Increase in Short Interest - MarketBeat
BeyondSpring (NASDAQ:BYSI) Shares Down 4.2% – Should You Sell? - Defense World
BeyondSpring (NASDAQ:BYSI) Trading Down 4.2%Should You Sell? - MarketBeat
Why ZIM Integrated Shipping Services Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Sahm
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Krystal Biotech (NASDAQ:KRYS) and BeyondSpring (NASDAQ:BYSI) Critical Survey - Defense World
Will BeyondSpring Inc. stock benefit from infrastructure spendingJuly 2025 Trade Ideas & Consistent Growth Equity Picks - Улправда
Can BeyondSpring Inc. stock weather global recessionJuly 2025 Breakouts & Weekly Return Optimization Alerts - Улправда
Will BeyondSpring Inc. stock benefit from sector rotationJuly 2025 Macro Moves & Breakout Confirmation Alerts - DonanımHaber
Will BeyondSpring Inc. stock benefit from AI adoptionMarket Weekly Review & Weekly Chart Analysis and Guides - Улправда
Pharma News: Will BeyondSpring Inc. stock outperform tech sector in 2025Quarterly Trade Summary & Low Risk Investment Opportunities - moha.gov.vn
Beyondspring Delays Second Closings of Share Sale - TipRanks
BeyondSpring Inc. Announces Preferred Share Purchase Agreement - TradingView — Track All Markets
BeyondSpring (NASDAQ: BYSI) now expects SEED share Second Closings in 1H 2026 - Stock Titan
BYSI: Recent Business Developments Shape Market Outlook - StocksToTrade
BeyondSpring Inc. Stock Shows Upward Spike As Earnings Report Uncovers Surprises - StocksToTrade
BeyondSpring Stock Faces Challenges Amid Recent Market Dynamics - timothysykes.com
BeyondSpring Inc. Faces Financial Pressure in the Pharmaceutical Market - timothysykes.com
BYSI Stock Shows Turbulence Amid Financial Uncertainty - StocksToTrade
BYSI Stock Volatility Amidst Strategic Developments and Market Shifts - StocksToTrade
BeyondSpring presents phase 3 DUBLIN-3 data at ESMO Asia Congress - MSN
BYSI’s Stock Roller Coaster: What Happens Next? - StocksToTrade
BeyondSpring Inc.’s Market Shift: Analyzing Financial Trends and Price Movements - timothysykes.com
BeyondSpring’s Stock Gains Steam Amid Market Developments - timothysykes.com
BeyondSpring Inc. (BYSI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
BeyondSpring (BYSI) Stock :Surges 5% as New Plinabulin Data Strengthens Case for Global NSCLC Registration Path - CoinCentral
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 - marketscreener.com
BYSI: BeyondSpring's Plinabulin Shows Promising Results in Phase 3 Trial - GuruFocus
BeyondSpring stock rises after positive Asian subset data from lung cancer trial - Investing.com Nigeria
BeyondSpring stock rises after positive Asian subset data from lung cancer trial By Investing.com - Investing.com South Africa
BeyondSpring reports positive Asian subset data for lung cancer drug By Investing.com - Investing.com Canada
BeyondSpring reports positive Asian subset data for lung cancer drug - Investing.com
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path - GlobeNewswire
BeyondSpring’s Plinabulin combination shows survival benefit in NSCLC - TipRanks
BeyondSpring (BYSI) Reports Promising Results for Plinabulin in Lung Cancer Study - GuruFocus
BeyondSpring Announces Positive Phase 3 DUBLIN-3 Results for Plinabulin in NSCLC Patients Post Anti-PD-(L)1 Therapy and Plans for Global DUBLIN-4 Trial - Quiver Quantitative
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025 - marketscreener.com
BeyondSpring (NASDAQ: BYSI) DUBLIN-3 finds 15.8-month OS, fewer brain mets in NSCLC - Stock Titan
Why 22nd Century Group Inc stock could benefit from AI revolutionTrade Ideas & Accurate Buy Signal Notifications - moha.gov.vn
BeyondSpring Inc. Reports Q3 2025 Earnings and Strategic Shift - MSN
What Wall Street predicts for BeyondSpring Inc. stock priceMarket Growth Report & Fast Momentum Entry Tips - Newser
Is BeyondSpring Inc. stock in correction or buying zone2025 Technical Overview & Safe Capital Growth Tips - Newser
Beyondspring Inc Stock (BYSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Beyondspring Inc Stock (BYSI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Decheng Capital China Life Sci | 10% Owner |
Oct 17 '25 |
Sale |
1.76 |
45,513 |
80,103 |
1,518,893 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 13 '25 |
Sale |
1.70 |
107,361 |
182,514 |
1,696,659 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 14 '25 |
Sale |
1.65 |
28,495 |
47,017 |
1,668,164 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 15 '25 |
Sale |
1.65 |
17,960 |
29,634 |
1,650,204 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 08 '25 |
Sale |
1.77 |
7,507 |
13,287 |
1,810,389 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 09 '25 |
Sale |
1.81 |
3,979 |
7,202 |
1,806,410 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 10 '25 |
Sale |
1.77 |
2,390 |
4,230 |
1,804,020 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 06 '25 |
Sale |
1.78 |
17,500 |
31,150 |
1,819,996 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 07 '25 |
Sale |
1.79 |
2,100 |
3,759 |
1,817,896 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 03 '25 |
Sale |
1.76 |
600 |
1,056 |
1,837,496 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):